The Zio patch is already on the market to check for a range of irregular heart conditions. It has a U.S. list price of $995 and is covered by most major insurers, according to the company.
What is the cost of a Zio Patch in the UK?
Innovative technology to detect abnormal heart rhythms is recommended for use by the NHS pending the collection of additional data. NICE has published medical technology guidance recommending the Zio XT service for detecting abnormal heart rhythms, but only if NHS organizations collect additional evidence of its benefits.
Patients will get access to this promising new technology for three years, during which time further data will be gathered to fill in evidence gaps about its efficacy. After this period, the NICE committee will assess the technology with the additional evidence and make a final judgment regarding whether Zio XT should be recommended for normal NHS usage.
More than 1.2 million people in the United Kingdom have been diagnosed with atrial fibrillation (AF), one of the most prevalent cardiac arrhythmias, an irregular heart rhythm. It is estimated that another 500,000 individuals are living with undiagnosed AF.
- If the NHS commissioned the Zio XT service, more than 150,000 individuals could utilize it.
- The Zio XT service consists of a water-resistant biosensor patch and a report with a summary of data analyzed by an artificial intelligence (AI)-driven algorithm.
- The biosensor patch is a compact, lightweight, and easy-to-wear electrocardiogram (ECG) that measures and records the electrical activity of the heart.
It is worn continuously for up to 14 days and may be fitted discreetly beneath the patient’s clothing at home. As the patch may be worn for up to two weeks, the quantity of data that can be analyzed is more than the 24-hour Holter monitor that is now the NHS standard, hence Zio XT is more likely to detect arrhythmia.
- The procedure may be contact-free, which is particularly advantageous during the COVID-19 epidemic, allowing the patient to have a telephone/video consultation before the Zio XT biosensor is sent directly to their house.
- Twelve hospital trusts in England are now evaluating the Zio XT service, which costs £265 per patient.
- The deputy chief executive and director of the Centre for Health Technology Evaluation at NICE, Meindert Boysen, stated, “This easy-to-use and innovative technology can aid in the detection of cardiac arrhythmias with continuous monitoring for up to 14 days, while allowing the patient to continue with their daily activities.
“Evidence indicates that Zio XT increases the number of individuals diagnosed with cardiac arrhythmias. The diagnostic accuracy of the system powered by artificial intelligence seems to be adequate for recognizing arrhythmias.
- While we are glad to support the usage of the Zio XT service, our committee has requested that further data be collected so that we can fully comprehend its impact on NHS resources and the long-term effects of its use.
- iRhythm technologies, the inventor of Zio XT, won the Accelerated Access Collaborative competition with NHSX and NIHR earlier this year.
- Indra Joshi, the director of AI at NHSX, stated, “We will be testing ZIO XT and a number of other cutting-edge technologies through our AI Lab in NHS services up and down the nation to determine if they can benefit patients in a safe manner and conserve resources.
- If the tests are successful, it may be possible for the NHS to deploy an important prospective heart disease screening tool on a larger scale.
- Zio XT is likely less expensive or comparable in cost to 24-hour Holter monitoring — a portable cardiac recording equipment fitted by a healthcare worker who puts electrodes on the patient’s chest to record their heartbeat for up to seven days.
Innovative technology to identify irregular cardiac rhythms is approved for NHS use by NICE pending more data collection.
New Data Support the Use of iRhythm’s ZIO® Service to Identify Cardiac Arrhythmias in Stroke and Transient Ischemic Attack (TIA) Patients SAN FRANCISCO, CALIFORNIA – February 13, 2014 – iRhythm Technologies, Inc., a healthcare information services firm, stated today that fresh research findings support the use of its ZIO Service to assist in identifying underlying cardiac arrhythmias in patients who have had a stroke or transient ischemic attack (TIA).
Using a noninvasive, tiny, wearable patch, the ZIO Service provides long-term, continuous monitoring to detect occasional heart rhythm problems, such as atrial fibrillation (AF), which is associated with an elevated risk of stroke. The new findings were presented as an abstract at the 2014 International Stroke Conference in San Diego, California, on Wednesday.
“Physicians need to know if stroke or TIA patients have an underlying cardiac arrhythmia that may have triggered their neurological episode,” said Maarten Lansberg, M.D., Ph.D., assistant professor of neurology and neurology sciences at Stanford University Medical Center.
- Current solutions for cardiac monitoring are limited in their capacity to detect arrhythmias and can be difficult for patients to use or endure.
- Due to their shorter wear lengths, standard Holter monitors would have missed a considerable proportion of arrhythmia episodes detected by the ZIO Patch in patients with stroke and transient ischemic attack.” For the study, researchers from Stanford reviewed data from 1,171 patients who wore the ZIO Patch to identify probable cardiac arrhythmias after a stroke or TIA.
They discovered that patients wore the monitor for an average of 10.9 days, which is substantially longer than the usual Holter monitor which is normally worn for 24-48 hours. In 4.8% of all reports, both symptomatic and asymptomatic AF was identified, whereas supraventricular tachycardia (SVT), a larger category of atrial arrhythmias excluding AF, was observed in 51% of cases.
In addition, the first episode of paroxysmal atrial fibrillation (PAF) occurred more than 48 hours after the start of monitoring in 14.3% of patients, implying it was overlooked by the Holter monitor. “The ZIO Service is becoming acknowledged as the new benchmark for monitoring patients with suspected arrhythmia,” stated Kevin King, president and CEO of iRhythm.
“This new study is significant because it demonstrates the diagnostic utility of the ZIO Service for stroke and TIA patients with underlying cardiac arrhythmias.” Regarding the ZIO Service The ZIO Service, which consists of the ZIO Patch, proprietary algorithms, and the ZIO Report, has been shown in many peer-reviewed studies to increase diagnostic yield and alter patient care compared to standard approaches to ambulatory electrocardiogram (ECG) monitoring.
The ZIO Patch is a noninvasive, water-resistant, easy-to-use, and discreet monitor that may be worn for up to 14 days, resulting in increased patient compliance and diagnostic yield. The massive volumes of acquired heartbeat data are analyzed by proprietary algorithms, and a brief report is sent to the patient’s physician.
In a recent research published in the American Journal of Medicine by the Scripps Translational Science Institute, it was revealed that the ZIO Service detected 57% more arrhythmia occurrences than the Holter monitor, mostly owing to longer monitoring.
- Since its commercial introduction in 2011, the ZIO Service has been utilized by more than two hundred thousand patients at approximately eight hundred institutions across the nation.
- The ZIO Service is covered for more than 170 million lives by prominent commercial payers and the majority of Medicare beneficiaries.
iRhythm Technologies, Inc.’s Background iRhythm is a privately held healthcare information services firm with aspirations of being the global leader in the management of cardiac arrhythmia information, a huge and expanding unmet clinical need. Its flagship service, the ZIO Service, provides a proven method to long-term continuous monitoring that enables early diagnosis to enhance patient outcomes and save healthcare costs.
How precise are Zio Patches?
They are missed. Holter Monitoring Systems. The long-term Zio monitor identifies almost 99% of arrhythmias in 14 days, but the short-term Holter monitor only detects 47% in 2 days.
Additional online resources ZioSuite is our efficient patient management platform. It facilitates patient enrollment and management, as well as report interpretation. Patients have access to online materials to assist them get started with Zio. Provide your patients with insurance coverage details.
Is Zio Patch covered by insurance?
All major commercial insurance policies cover Zio. Depending on their plan and coverage, patients may be responsible for out-of-pocket expenses. The amount due is established by the patient’s insurance carrier and may include a co-payment, co-insurance, or deductible.
How precise are Zio Patches?
They are missed. Holter Monitoring Systems. The long-term Zio monitor identifies almost 99% of arrhythmias in 14 days, but the short-term Holter monitor only detects 47% in 2 days.